Thermo Fisher Scientific Inc (TMO): Price and Financial Metrics
Thermo Fisher Scientific Inc (TMO)
Today's Latest Price: $468.76 USD
Updated Oct 21 6:40pm
Add TMO to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 58 in Medical - Diagnostics/Research
See all "A" rated Strong Buy stocks
TMO Stock Summary
- Thermo Fisher Scientific Inc's market capitalization of $185,436,487,144 is ahead of 99.19% of US-listed equities.
- Thermo Fisher Scientific Inc's stock had its IPO on September 1, 1987, making it an older stock than 91.57% of US equities in our set.
- The price/operating cash flow metric for Thermo Fisher Scientific Inc is higher than 89.01% of stocks in our set with a positive cash flow.
- Stocks with similar financial metrics, market capitalization, and price volatility to Thermo Fisher Scientific Inc are DHR, CMCSA, T, PEP, and NVO.
- TMO's SEC filings can be seen here. And to visit Thermo Fisher Scientific Inc's official web site, go to www.thermofisher.com.
TMO Stock Price Chart Interactive Chart >
TMO Price/Volume Stats
| Current price | $468.76 | 52-week high | $478.99 |
| Prev. close | $465.26 | 52-week low | $250.21 |
| Day low | $462.42 | Volume | 2,212,900 |
| Day high | $478.99 | Avg. volume | 1,654,520 |
| 50-day MA | $434.58 | Dividend yield | 0.19% |
| 200-day MA | $363.39 | Market Cap | 185.44B |
Thermo Fisher Scientific Inc (TMO) Company Bio
Thermo Fisher Scientific provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics worldwide. The company was founded in 1956 and is based in Waltham, Massachusetts.
TMO Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $468.76 | $156.99 | -66% |
We started the process of determining a valid price forecast for Thermo Fisher Scientific Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Thermo Fisher Scientific Inc ranked in the 23th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Thermo Fisher Scientific Inc, consider:
- The company's balance sheet shows it gets 90% of its capital from equity, and 10% of its capital from debt. Its equity weight surpasses that of 61% of free cash flow generating stocks in the Healthcare sector.
- The business' balance sheet reveals debt to be 10% of the company's capital (with equity being the remaining amount). Approximately merely 24.13% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -67% |
| 1% | -67% |
| 2% | -66% |
| 3% | -66% |
| 4% | -66% |
| 5% | -65% |
REPH, BAX, GMED, MDT, and OFIX can be thought of as valuation peers to TMO, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...